



HAL
open science

Switch des anti-calcineurines au Belatacept chez les patients transplantés rénaux présentant un rejet humoral chronique-actif

Tristan de Nattes

► **To cite this version:**

Tristan de Nattes. Switch des anti-calcineurines au Belatacept chez les patients transplantés rénaux présentant un rejet humoral chronique-actif. Médecine humaine et pathologie. 2020. dumas-02965193

HAL Id: dumas-02965193

<https://dumas.ccsd.cnrs.fr/dumas-02965193>

Submitted on 13 Oct 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Par délibération en date du 3 mars 1967, la faculté a arrêté que les opinions émises dans les dissertations qui lui seront présentées doivent être considérées comme propres à leurs auteurs et qu'elle n'entend leur donner aucune approbation ni improbation.

ANNEE UNIVERSITAIRE 2019 - 2020

U.F.R. SANTÉ DE ROUEN

DOYEN : **Professeur Benoît VEBER**

ASSESSEURS : **Professeur Michel GUERBET**
Professeur Agnès LIARD
Professeur Guillaume SAVOYE

I - MEDECINE

PROFESSEURS DES UNIVERSITES – PRATICIENS HOSPITALIERS

Mr Frédéric ANSELME	HCN	Cardiologie
Mme Gisèle APTER	Havre	Pédopsychiatrie
Mme Isabelle AUQUIT AUCKBURH	HCN	Chirurgie plastique
Mr Jean-Marc BASTE	HCN	Chirurgie Thoracique
Mr Fabrice BAUER	HCN	Cardiologie
Mme Soumeya BEKRI	HCN	Biochimie et biologie moléculaire
Mr Ygal BENHAMOU	HCN	Médecine interne
Mr Jacques BENICHOU	HCN	Bio statistiques et informatique médicale
Mr Olivier BOYER	UFR	Immunologie
Mme Sophie CANDON	HCN	Immunologie
Mr François CARON	HCN	Maladies infectieuses et tropicales
Mr Philippe CHASSAGNE	HCN	Médecine interne (gériatrie)
Mr Vincent COMPERE	HCN	Anesthésiologie et réanimation chirurgicale
Mr Jean-Nicolas CORNU	HCN	Urologie
Mr Antoine CUVELIER	HB	Pneumologie

Mr Jean-Nicolas DACHER	HCN	Radiologie et imagerie médicale
Mr Stéfan DARMONI communication	HCN	Informatique médicale et techniques de communication
Mr Pierre DECHELOTTE	HCN	Nutrition
Mr Stéphane DERREY	HCN	Neurochirurgie
Mr Frédéric DI FIORE	CHB	Cancérologie
Mr Fabien DOGUET	HCN	Chirurgie Cardio Vasculaire
Mr Jean DOUCET	SJ	Thérapeutique - Médecine interne et gériatrie
Mr Bernard DUBRAY	CHB	Radiothérapie
Mr Frank DUJARDIN	HCN	Chirurgie orthopédique - Traumatologique
Mr Fabrice DUPARC traumatologique	HCN	Anatomie - Chirurgie orthopédique et traumatologique
Mr Eric DURAND	HCN	Cardiologie
Mr Bertrand DUREUIL	HCN	Anesthésiologie et réanimation chirurgicale
Mme Hélène ELTCHANINOFF	HCN	Cardiologie
Mr Manuel ETIENNE	HCN	Maladies infectieuses et tropicales
Mr Thierry FREBOURG	UFR	Génétique
Mr Pierre FREGER (<i>surnombre</i>)	HCN	Anatomie - Neurochirurgie
Mr Jean François GEHANNO	HCN	Médecine et santé au travail
Mr Emmanuel GERARDIN	HCN	Imagerie médicale
Mme Priscille GERARDIN	HCN	Pédopsychiatrie
M. Guillaume GOURCEROL	HCN	Physiologie
Mr Dominique GUERROT	HCN	Néphrologie
Mr Olivier GUILLIN	HCN	Psychiatrie Adultes
Mr Claude HOUDAYER	HCN	Génétique
Mr Fabrice JARDIN	CHB	Hématologie
Mr Luc-Marie JOLY	HCN	Médecine d'urgence
Mr Pascal JOLY	HCN	Dermato – Vénérologie
Mme Bouchra LAMIA	Havre	Pneumologie
Mme Annie LAQUERRIERE	HCN	Anatomie et cytologie pathologiques
Mr Vincent LAUDENBACH	HCN	Anesthésie et réanimation chirurgicale
Mr Joël LECHEVALLIER	HCN	Chirurgie infantile

Mr Hervé LEFEBVRE	HB	Endocrinologie et maladies métaboliques
Mr Thierry LEQUERRE	HCN	Rhumatologie
Mme Anne-Marie LEROI	HCN	Physiologie
Mr Hervé LEVESQUE	HCN	Médecine interne
Mme Agnès LIARD-ZMUDA	HCN	Chirurgie Infantile
Mr Pierre Yves LITZLER	HCN	Chirurgie cardiaque
Mr Bertrand MACE	HCN	Histologie, embryologie, cytogénétique
M. David MALTETE	HCN	Neurologie
Mr Christophe MARGUET	HCN	Pédiatrie
Mme Isabelle MARIE	HCN	Médecine interne
Mr Jean-Paul MARIE	HCN	Oto-rhino-laryngologie
Mr Loïc MARPEAU	HCN	Gynécologie - Obstétrique
Mr Stéphane MARRET	HCN	Pédiatrie
Mme Véronique MERLE	HCN	Epidémiologie
Mr Pierre MICHEL	HCN	Hépto-gastro-entérologie
M. Benoit MISSET (<i>détachement</i>)	HCN	Réanimation Médicale
Mr Marc MURAINÉ	HCN	Ophthalmologie
Mr Christophe PEILLON	HCN	Chirurgie générale
Mr Christian PFISTER	HCN	Urologie
Mr Jean-Christophe PLANTIER	HCN	Bactériologie - Virologie
Mr Didier PLISSONNIER	HCN	Chirurgie vasculaire
Mr Gaëtan PREVOST	HCN	Endocrinologie
Mr Jean-Christophe RICHARD (<i>détachement</i>)	HCN	Réanimation médicale - Médecine d'urgence
Mr Vincent RICHARD	UFR	Pharmacologie
Mme Nathalie RIVES	HCN	Biologie du développement et de la reproduction
Mr Horace ROMAN (<i>disponibilité</i>)	HCN	Gynécologie - Obstétrique
Mr Jean-Christophe SABOURIN	HCN	Anatomie – Pathologie
Mr Mathieu SALAUN	HCN	Pneumologie
Mr Guillaume SAVOYE	HCN	Hépto-gastrologie
Mme Céline SAVOYE-COLLET	HCN	Imagerie médicale
Mme Pascale SCHNEIDER	HCN	Pédiatrie
Mr Lilian SCHWARZ	HCN	Chirurgie Viscérale et Digestive

Mr Michel SCOTTE	HCN	Chirurgie digestive
Mme Fabienne TAMION	HCN	Thérapeutique
Mr Luc THIBERVILLE	HCN	Pneumologie
Mr Hervé TILLY (<i>surnombre</i>)	CHB	Hématologie et transfusion
M. Gilles TOURNEL	HCN	Médecine Légale
Mr Olivier TROST	HCN	Anatomie -Chirurgie Maxillo-Faciale
Mr Jean-Jacques TUECH	HCN	Chirurgie digestive
Mr Benoît VEBER	HCN	Anesthésiologie - Réanimation chirurgicale
Mr Pierre VERA	CHB	Biophysique et traitement de l'image
Mr Eric VERIN	Les Herbiers	Médecine Physique et de Réadaptation
Mr Eric VERSPYCK	HCN	Gynécologie obstétrique
Mr Olivier VITTECOQ	HC	Rhumatologie
Mme Marie-Laure WELTER	HCN	Physiologie

MAITRES DE CONFERENCES DES UNIVERSITES – PRATICIENS HOSPITALIERS

Mme Najate ACHAMRAH	HCN	Nutrition
Mme Noëlle BARBIER-FREBOURGH	HCN	Bactériologie – Virologie
Mr Emmanuel BESNIER	HCN	Anesthésiologie - Réanimation
Mme Carole BRASSE LAGNEL	HCN	Biochimie
Mme Valérie BRIDOUX HUYBRECHTS	HCN	Chirurgie Vasculaire
Mr Gérard BUCHONNET	HCN	Hématologie
Mme Mireille CASTANET	HCN	Pédiatrie
Mme Nathalie CHASTAN	HCN	Neurophysiologie
Mr Moïse COEFFIER	HCN	Nutrition
Mr Serge JACQUOT	UFR	Immunologie
Mr Joël LADNER	HCN	Epidémiologie, économie de la santé
Mr Jean-Baptiste LATOUCHE	UFR	Biologie cellulaire
M. Florent MARGUET	HCN	Histologie
Mme Chloé MELCHIOR	HCN	Gastroentérologie
Mr Thomas MOUREZ (<i>détachement</i>)	HCN	Virologie

Mr Gaël NICOLAS	UFR	Génétique
Mme Muriel QUILLARD	HCN	Biochimie et biologie moléculaire
Mme Laëtitia ROLLIN	HCN	Médecine du Travail
Mme Pascale SAUGIER-VEBER	HCN	Génétique
Mme Anne-Claire TOBENAS-DUJARDIN	HCN	Anatomie
Mr David WALLON	HCN	Neurologie
Mr Julien WILS	HCN	Pharmacologie

PROFESSEUR AGREGE OU CERTIFIE

Mr Thierry WABLE	UFR	Communication
Mme Mélanie AUVRAY-HAMEL	UFR	Anglais

II - PHARMACIE

PROFESSEURS DES UNIVERSITES

Mr Jérémy BELLIEN (PU-PH)	Pharmacologie
Mr Thierry BESSON	Chimie Thérapeutique
Mr Jean COSTENTIN (Professeur émérite)	Pharmacologie
Mme Isabelle DUBUS	Biochimie
Mr Abdelhakim EL OMRI	Pharmacognosie
Mr François ESTOUR	Chimie Organique
Mr Loïc FAVENNEC (PU-PH)	Parasitologie
Mr Jean Pierre GOULLE (Professeur émérite)	Toxicologie
Mr Michel GUERBET	Toxicologie
Mme Christelle MONTEIL	Toxicologie
Mme Martine PESTEL-CARON (PU-PH)	Microbiologie
Mr Rémi VARIN (PU-PH)	Pharmacie clinique
Mr Jean-Marie VAUGEOIS	Pharmacologie
Mr Philippe VERITE	Chimie analytique

MAITRES DE CONFERENCES DES UNIVERSITES

Mme Cécile BARBOT	Chimie Générale et Minérale
Mr Frédéric BOUNOURE	Pharmacie Galénique
Mr Thomas CASTANHEIRO MATIAS	Chimie Organique
Mr Abdeslam CHAGRAOUI	Physiologie
Mme Camille CHARBONNIER (LE CLEZIO)	Statistiques
Mme Elizabeth CHOSSON	Botanique
Mme Marie Catherine CONCE-CHEMTOB	Législation pharmaceutique et économie de la santé
Mme Cécile CORBIERE	Biochimie
Mme Nathalie DOURMAP	Pharmacologie
Mme Isabelle DUBUC	Pharmacologie
Mme Dominique DUTERTE- BOUCHER	Pharmacologie
Mr Gilles GARGALA (MCU-PH)	Parasitologie
Mme Nejla EL GHARBI-HAMZA	Chimie analytique
Mme Marie-Laure GROULT	Botanique
Mr Hervé HUE	Biophysique et mathématiques
Mme Hong LU	Biologie
Mme Marine MALLETER	Toxicologie
M. Jérémie MARTINET (MCU-PH)	Immunologie
Mme Tiphaine ROGEZ-FLORENT	Chimie analytique
Mr Mohamed SKIBA	Pharmacie galénique
Mme Malika SKIBA	Pharmacie galénique
Mme Christine THARASSE	Chimie thérapeutique
Mr Frédéric ZIEGLER	Biochimie

PROFESSEURS ASSOCIES

Mme Cécile GUERARD-DETUNCQ	Pharmacie officinale
Mme Caroline BERTOUX	Pharmacie

PAU-PH

M. Mikaël **DAOUPHARS**

PROFESSEUR CERTIFIE

Mme Mathilde **GUERIN** Anglais

ASSISTANTS HOSPITALO-UNIVERSITAIRES

Mme Alice **MOISAN** Virologie

M. Henri **GONDÉ** Pharmacie

ATTACHES TEMPORAIRES D'ENSEIGNEMENT ET DE RECHERCHE

M. Abdel **MOUHAJIR** Parasitologie

M. Maxime **GRAND** Bactériologie

ATTACHE TEMPORAIRE D'ENSEIGNEMENT

Mme Ramla **SALHI** Pharmacognosie

<p>LISTE DES RESPONSABLES DES DISCIPLINES PHARMACEUTIQUES</p>
--

Mme Cécile **BARBOT** Chimie Générale et minérale

Mr Thierry **BESSON** Chimie thérapeutique

Mr Abdeslam **CHAGRAOUI** Physiologie

Mme Elisabeth **CHOSSON** Botanique

Mme Marie-Catherine **CONCE-CHEMTOB** Législation et économie de la santé

Mme Isabelle **DUBUS** Biochimie

Mr Abdelhakim **EL OMRI** Pharmacognosie

Mr François **ESTOUR** Chimie organique

Mr Loïc **FAVENNEC** Parasitologie

Mr Michel **GUERBET** Toxicologie

Mme Martine **PESTEL-CARON**

Microbiologie

Mr Mohamed **SKIBA**

Pharmacie galénique

Mr Rémi **VARIN**

Pharmacie clinique

M. Jean-Marie **VAUGEOIS**

Pharmacologie

Mr Philippe **VERITE**

Chimie analytique

III – MEDECINE GENERALE

PROFESSEUR MEDECINE GENERALE

Mr Jean-Loup **HERMIL** (PU-MG) UFR Médecine générale

MAITRE DE CONFERENCE MEDECINE GENERALE

Mr Matthieu **SCHUERS** (MCU-MG) UFR Médecine générale

PROFESSEURS ASSOCIES A MI-TEMPS – MEDECINS GENERALISTE

Mr Emmanuel **LEFEBVRE** UFR Médecine Générale

Mme Elisabeth **MAUVIARD** UFR Médecine générale

Mr Philippe **NGUYEN THANH** UFR Médecine générale

Mme Yveline **SEVRIN** UFR Médecine générale

Mme Marie Thérèse **THUEUX** UFR Médecine générale

MAITRE DE CONFERENCES ASSOCIE A MI-TEMPS – MEDECINS GENERALISTES

Mr Pascal **BOULET** UFR Médecine générale

Mme Laëtitia **BOURDON** UFR Médecine Générale

Mr Emmanuel **HAZARD** UFR Médecine Générale

Mme Lucile **PELLERIN** UFR Médecine générale

ENSEIGNANTS MONO-APPARTENANTS

PROFESSEURS

Mr Paul **MULDER** (phar) Sciences du Médicament
Mme Su **RUAN** (med) Génie Informatique

MAITRES DE CONFERENCES

Mr Sahil **ADRIOUCH** (med) Biochimie et biologie moléculaire (Unité Inserm 905)
Mme Gaëlle **BOUGEARD-DENOYELLE** (med) Biochimie et biologie moléculaire (UMR 1079)
Mme Carine **CLEREN** (med) Neurosciences (Néovasc)
M. Sylvain **FRAINEAU** (med) Physiologie (Inserm U 1096)
Mme Pascaline **GAILDRAT** (med) Génétique moléculaire humaine (UMR 1079)
Mr Nicolas **GUEROUT** (med) Chirurgie Expérimentale
Mme Rachel **LETELLIER** (med) Physiologie
Mr Antoine **OUVRARD-PASCAUD** (med) Physiologie (Unité Inserm 1076)
Mr Frédéric **PASQUET** Sciences du langage, orthophonie
Mme Christine **RONDANINO** (med) Physiologie de la reproduction
Mr Youssan Var **TAN** Immunologie
Mme Isabelle **TOURNIER** (med) Biochimie (UMR 1079)

CHEF DES SERVICES ADMINISTRATIFS : Mme Véronique DELAFONTAINE

HCN - Hôpital Charles Nicolle

HB - Hôpital de BOIS GUILLAUME

*CB - Centre Henri Becquerel
Rouvray*

CHS - Centre Hospitalier Spécialisé du

*CRMPR - Centre Régional de Médecine Physique et de Réadaptation
Rouen*

SJ – Saint Julien

Table of contents

Remerciements	14
<i>Switch from Calcineurin Inhibitors to Belatacept in Kidney Transplant patients with chronic-active Antibody Mediated Rejection results in a lower decline in Kidney Transplant function at three years.</i>	19
Abbreviations.....	19
Abstract	20
Introduction	21
Material and methods	22
Results	23
Discussion	30
Conclusion	35
Figure legends	36
References	38
Tables	41
Table 1	41
Table 2	43
Table 3	44
Figures	45
Figure 1	45
Figure 2	46
Figure 3	47
Figure 4	48
Figure 5	49

Remerciements

A mon jury de thèse :

- A Dominique Guerrot. Il y a 5 ans, tu m'as appelé pour vanter les mérites de la néphrologie rouennaise. Comme je venais de me lever et que je ne savais pas encore qui tu étais, je ne savais pas de quelle ville on me parlait, ni que c'était le chef de service qui m'appelait. Tu as manifestement réussi ton coup : me voilà maintenant rouennais. Tes connaissances, ta rigueur et ta disponibilité sont des exemples à suivre. A toutes les étapes de mon internat et de mes réflexions sur mon cursus, tu m'as soutenu et aidé. Me voilà maintenant lancé dans l'aventure une thèse de sciences et à chercher un appartement à Londres... J'espère être digne de la confiance que tu m'as témoignée et ne jamais te faire regretter cet appel.

- A Dominique Bertrand, « une main de fer dans un gant de velours ». La première fois que je t'ai vu, je me suis demandé qui était ce médecin chevelu en train de s'énerver au téléphone (probablement le manque de disponibilité d'un bloc ?). Je te dois beaucoup : tu m'as fait découvrir le monde de la transplantation, mais pas que. Tu m'as montré une façon d'être avec les patients que je ne connaissais pas, à la fois proche, rassurant, honnête, et j'en passe ; de l'enthousiasme pour les projets nouveaux ; du calme sur les moments compliqués... « Alors écoute moi bien » : merci.

- A Sophie Candon. Merci de m'avoir accueilli au laboratoire et de t'être lancée avec moi dans ce projet de biologie moléculaire. Je suis heureux de découvrir à tes côtés l'immunologie et je suis sûr qu'au fil de nos projets, nous arriverons de mieux en mieux à communiquer ! Cette thèse ne parle pas beaucoup d'alloréactivité, je ferai mieux la prochaine fois promis !

- Au bon Professeur Mesnard, représentant de la maison mère. Merci à toi et à l'UNTR de m'avoir donné envie de faire de la néphrologie, puis de m'avoir envoyé à Rouen, et maintenant de juger ce travail de thèse. Dès l'externat, tu me disais d'être curieux et de me poser des questions. Je garde précieusement ces conseils et tache de les appliquer au mieux.

Merci à tous les « seniors » rencontrés au fil de mon parcours :

- Au Professeur Eric Rondeau : « on ne fait pas à boire à un âne qui n'a pas soif ». J'espère que ce proverbe entendu chez vous ne me sera jamais destiné.

- A Cédric Rafat. Dès l'externat tu m'as impressionné. Ta passion, ta motivation, ta volonté d'aller jusqu'au bout sont pour moi des exemples à suivre. Merci de ta patience pour l'article : avoir en dernier auteur un des premiers qui m'a donné envie de faire de la néphrologie signifie beaucoup pour moi.

- A Mélanie Hanoy, premières visites d'interne avec toi, en dialyse, dans une ville que je ne connais pas... A Frank Le Roy, pour ta rigueur et les anecdotes sur « l'histoire de la dialyse ». Je vous remercie tous les deux de rendre ses lettres de noblesses à la dialyse. A vous deux, vos enseignements quoique différents se complètent et nous donnent envie de toujours chercher à mieux faire pour nos patients. Soyez rassurés : j'aime aussi la dialyse !

- A Lise Lelandais, ma CCA de néphro B. Merci pour ton enseignement patient en néphro (« oui Tristan tu peux mettre 3 Diffu K au lieu de 2 »), en transplantation (« non pas de patch aortique sur un prélèvement donneur vivant... »), en gestes (« c'est la veine qu'il faut viser hein ») ... Je te dois beaucoup.

- Merci à tous les autres de néphrologie, avec qui j'ai moins travaillé : Charlotte, Isabelle, Ludivine, MCL, Mathilde, Mouad, Philippe...

- Merci à Yosu Luque pour ses nombreuses et enrichissantes visites, pour les KT enlevés aux patients anuriques et pour les examens orthopédiques approfondis.

Merci à tous les internes avec qui nous nous sommes serré les coudes.

- Audrey, quand je suis arrivé premier semestre, faire 6 mois avec toi a été un très bon modèle de rigueur et je t'en remercie.

- A ma Roperch, pour ces verres que nous avons pris à la fin de ces longues journées en néphro B, tes pas de danse, et cette colocation havraise finalement assez courte pour notre plus grand bonheur à tous les quatre. Ta gentillesse et ton humanité, que ce soit avec tes proches ou les patients sont précieuses. Te voir ainsi épanoui est un réel plaisir.

- A Anaïs, tu n'as pas toujours été tendre avec moi, mais il faut dire que mes sollicitations havraises étaient un peu trop nombreuses. Te voir tout donner pour les patients est un exemple à suivre.

- A Alexandre, malgré 12 mois de stage ensemble tu n'auras pas eu raison de moi. Merci pour ton amitié, ta bonne humeur au quotidien, tes calembours ravageurs, tes explications incompréhensibles sur les systèmes hifi et tes musiques de sauvage. Je m'excuse de ne pas être venu voir le carillon de Kortrijk mais ne te sers pas de ça pour ne pas prendre l'Eurostar ! Merci pour les bons moments que nous passons aussi bien tous les 2 que tous les 3. Merci pour l'accueil royal au Trait.

- A la magnifique team de maladies infectieuses : merci Anissa d'avoir vu toutes les familles à notre place et pour « le point Anissa » de fin de staff, merci à Julieeeeeeeeeette l'experte canari, merci Gaspard pour les ponctions lombaires en HDJ, merci Nicolas pour cette fabuleuse

soirée de fin de stage chez toi. Ce groupe whatsapp que nous cachions si bien en staff reste une source inépuisable de blagues. On serait chocolat s'il disparaissait.

- A Hanae, Maryline et Charles, pour m'avoir appris toutes les façons de dire « non mais c'est pas cardio ».

- A Margaux, je te souhaite beaucoup de courage dans cette aventure podocytaire, ton talent n'a de limite que ta vitesse de course, c'est vous dire ! A Maxime qui a succombé aux charmes de la réanimation.

- Aux anapath : qui aime bien châtie bien. A PAT qui cache bien son jeu, à Gwenaëlle et Guillaume : vivent les mariés (on ne dit pas merci au wedding planner ?), à JOC (qui est la meilleure ?), à Madame Hélène, aux têtes fémorales.

- A l'équipe de dialyse, je ne peux pas citer tout le monde (les remerciements sont tout de même censés être plus courts que la thèse...) mais vous savez bien que le cœur y est. Merci d'avoir accueilli un petit bézot parisien tout perdu, d'avoir été là dans les bons moments mais aussi les moins bons, pour votre accompagnement bienveillant. J'ai hâte de retravailler avec vous. Stéphanie, finalement il n'y aura pas eu de poulet du Dimanche chez bonne-maman, mais on pourra toujours faire un poulet du Dimanche !

- A l'équipe du 1^{er} étage. Malgré les retards au staff du matin, les pres modifiées 10 fois de suite, les bio rajoutées « non mais là c'est vraiment super urgent », les papiers de sortie presque prêts, vous gardez la volonté de tout faire (et le faire bien !) pour nos patients. Nous avons beaucoup de chance de vous avoir en néphrologie.

- A Baptiste pour ces trois mois remplis de bonnes blagues. A Apolline pour les planches en terrasse, à Vincent avec qui je n'aurais pas eu le plaisir de travailler mais on se rattrape en buvant des coups, Charlotte & Xavier qui connaissent tous les bons restos, à ceux du Havre...

- A tous les autres avec qui j'ai pu travailler, les plus vieux qui sont partis plus ou moins loin, les plus jeunes prometteurs. Merci aux patients et à leurs histoires, aux grincheux, aux sympa, à ceux qui font pleurer, à ceux qui font rire (parfois à leurs dépens), aux vieux de la vieille qui ont fait semblant de me faire confiance au début.

Merci aux amis

- Au quatuor Cépage, cépajuste, cépajoli, cépaenplace... et à Geneviève bien sûr: 10 ans avec vous, ce n'est pas rien (les mauvaises langues diront « tout ça pour ça ? »). Aux répétitions où j'arrivais en retard, si j'arrivais (quelle idée aussi, 9h un Samedi matin...), aux fou-rires que nous avons eu aux moments où il ne faut pas les avoir, aux « guests » qui n'ont étonnement pas souhaiter donner suite avec nous, aux « missions » de la mairie, à nos déguisements de haute-voltige... Pendant ces longues études, vous étiez une bouffée d'oxygène. Nous menons chacun des vies différentes maintenant, et pourtant nous gardons la même relation.

- A Emilien, l'USIH (aka « le régime sans selles »), l'HDJ ok chimio, Zizouille et la relation médecin-malade, la gynéco (je crois que tout y est)... Puis les conf, les sous-khôles, les PMZ, les questionnements (non mais c'est pas si mal Vesoul comme ville je crois ?)... Tout autant d'histoires que je m'empresserai de raconter à Judith (possiblement avec un coup dans le nez : « et l'histoire de ton papa qui s'est évanoui, tu la connais ? »). Avoir « grandi » au sein de la

fac à tes côtés m'a été d'une grande aide. Ton seul défaut serait-il de ne pas être néphro ? Merci à Elise de m'avoir accueilli chez vous de nombreuses fois sans sourcilier.

- A Vincent « zéro à la question, zéro au dossier, zéro aux ECN » et à Karldiologue pour cette task-force de révisions.

- A Gaïa, le petit mouton, « la fille qui lit des livres » du collègue. Désolé de t'avoir emmené à Argentièrre alors qu'il ne neigeait « pas tant que ça ». Nous avons passé tant de soirées ensemble pendant ces études qu'à la fin, toi aussi tu es un peu médecin. Merci d'avoir été cette soupape de décompression pendant tant d'années (et ce n'est pas fini). Nos avis divergent parfois, parfois on s'énerve mutuellement un peu, mais nous trouvons toujours une bonne bouteille pour se rabibocher. Tu seras toujours la bienvenue à la campagne. A tes parents qui ont été bien gentil ne rien dire alors que je débarquais à n'importe quelle heure. Et si au lieu de profiter du soleil de l'été on partait au fin fond de la Patagonie en plein hiver ?

- A Annabelle, une urologue et un néphrologue, forcément parfois ça se chamaille. J'ai hâte de t'appeler en pleine nuit pour une greffe, ça promet des débriefings musclés ;) A Paul, tu as quelques progrès à faire en belote encore, mais on ne peut pas être un guépard dans tous les domaines. A nos futurs réunions « vidage de sac ».

-Aux copains du M2, peut-être la première pierre d'un groupe inter-régional de transplantation ? A Valou et nos covoturages (ce projet d'émission-interview-voiture est vraiment une bonne idée) ; à Mathieu et Diane la michto.

Merci à ma famille

- Merci à mes grands-parents, sans qui je n'en serai certainement pas là. A ma mamie pour ton amour, pour ce goût du travail inculqué dès le plus jeune âge. J'ai peut-être un peu soupiré parfois quand il fallait travailler pour avancer les devoirs de toute la semaine, mais ce sont des souvenirs que je chérirai toute ma vie. A mon papi qui m'a quasiment tout appris : le vélo, la piscine, la barque, la voiture, et je dois en oublier. Tu as aussi essayé la gravure et le dessin, mais il faut admettre que ce n'était pas mon fort. Merci à tous les deux d'avoir toujours été là pour moi, d'avoir cru en moi, merci pour les vacances en Bretagne qui avec les années se sont transformées en séances de révisions face à l'eau où je n'avais qu'à me mettre les pieds sous la table.

- Merci à mamie Annie pour les bons moments que nous passons ensemble, aussi bien tous les 2 que tous les 3. Tu as immédiatement accueilli Charlotte avec beaucoup d'amour et je t'en remercie. Merci de nous requinquer à coup de langoustines, d'apéro, de promenade au port (et de douches chaudes) après nos semaines de navigation.

- Merci à mes parents. Merci de m'avoir soutenu pendant ces longues années d'études. Sans vous, ça n'aurait pas été possible. A papa, malgré cette thèse et le titre de docteur, je ne pourrai toujours rien faire pour ton rhume à part de dire de te moucher. A maman qui a pu pleinement profiter de mes sautes d'humeur de la P1 à la D4, et qui pourtant ne m'en a pas tenu rigueur.

- Merci à Gwendal de m'avoir appris à travailler en faisant abstraction de l'environnement ambiant, merci d'être là. Désolé que cette thèse ne parle pas de fistule, je sais pourtant que tu les apprécies. Marin tu as beau avoir 21 ans, tu seras toujours mon petit bonhomme. L'avenir musical de la famille repose maintenant uniquement sur toi, j'ai confiance en ton talent et en ta capacité de travail.

- A Tonton pour sa capacité à trouver des activités calmes pour gérer tous les enfants en vacances, à Louis que je guette maintenant dans les génériques et à Lola, j'espère que j'aurai des réducs quand tu prendras soin de mon violoncelle ! A la gazette du Pont-Lorais.

- A Françoise et Guy, les marcheurs globe-trotter. Merci pour ces moments que nous partageons ensemble, vos messages d'encouragement, et votre enthousiasme à toute épreuve. Merci d'être toujours disponibles quand nous avons besoin de vous et de soutenir autant votre petite-fille que votre beau-petit-fils.

- A mes beaux-parents. Londres sera un peu plus loin que Rouen pour venir, mais on trouvera une place pour vous dans l'appartement ;) Merci de m'avoir accueilli dans votre famille comme vous l'avez fait. Merci de votre soutien et votre aide pendant l'internat (et pour les travaux !). Merci à Lucile de te plier en quatre pour nous, merci à Laurent pour ta bienveillance à mon égard.

- A ma Charlotte. A cette garde aux urgences où nous nous sommes rencontrés. Merci de changer ma vie comme tu le fais, de me suivre dans de grandes aventures comme le catamaran sur une île déserte, de rire à mes blagues. Depuis 4 ans nous avons déjà vécu beaucoup de choses, et ce n'est que le début de notre histoire. Je t'aime.

Switch from Calcineurin Inhibitors to Belatacept in Kidney Transplant patients with chronic-active Antibody Mediated Rejection results in a lower decline in Kidney Transplant function at three years.

Abbreviations

AMBR: Antibody Mediated Rejection

ca-ABMR: chronic-active Antibody Mediated Rejection

CNI: Calcineurin Inhibitors

D0: Day 0

DSA: Donor Specific Antibodies

eGFR: estimated Glomerular Filtration Rate

HR: Hazard Ratio

KT: Kidney Transplantation

MFI: Mean Fluorescence Intensity

Abstract

Introduction:

Chronic-active Antibody Mediated Rejection (ca-ABMR) in Kidney Transplant (KT) lacks effective treatment. Hence, latest guidelines recommend usual nephroprotective therapies in which limiting nephrotoxicity is paramount. Belatacept which usefulness in Extended Criteria Donors and chronic vascular changes has been shown could be an interesting alternative to Calcineurin Inhibitors (CNI). This study aims to evaluate if switch from CNI to Belatacept is beneficial on KT survival and function in ca-ABMR.

Methods:

Patients with the diagnosis of ca-ABMR and switched to Belatacept between 2012 and 2020 in four French KT centers were retrospectively included.

Results:

Nineteen patients were switched from CNI to Belatacept and compared to 58 controls with a median follow-up of 29 [4 - 125] months. Biopsy was performed 78 [4 - 140] months after KT, with a mean estimated Glomerular Filtration Rate (eGFR) of 36.2 ± 15.6 mL/min/1.73m².

There was no difference of eGFR at baseline, one, two and three years: 31.2 ± 14.5 , 26.0 ± 19.7 , 22.4 ± 19.5 and 22.1 ± 24.9 mL/min/1.73m², respectively, in the Belatacept-treated group, versus 36.1 ± 15.7 , 29.1 ± 18.6 , 23.4 ± 18.0 and 17.5 ± 18.0 mL/min/1.73m² in the CNI-treated group. The delta of eGFR between 3 years and Day 0 was -9.1 ± 14.3 mL/min/1.73m² in the Belatacept-treated group versus -18.6 ± 15.1 mL/min/1.73m², $p = 0.05$. This difference was increased when focusing on the subgroup with a baseline eGFR ≥ 35 mL/min/1.73m²: 3.3 ± 19.2 versus -25.3 ± 17.1 mL/min/1.73m², $p = 0.005$. However, death-censored survival was similar in the two groups at one, two and three years: 81.3%, 71.4% and 41.6%, respectively, in the Belatacept-treated group, versus 84.4%, 66.0% and 47.1%, $p = 0.6$.

Conclusion:

Switch from CNI to Belatacept may lower decline of eGFR at three years, especially when it is started at an early stage. However, it does not appear to have an effect on death-censored KT survival.

Introduction

Despite advances in management of Antibody Mediated Rejection (ABMR) in Kidney Transplant (KT) patients, it still remains a major cause of estimated Glomerular Filtration Rate (eGFR) alteration and graft loss (1). Human Leukocyte Antigen (HLA) and non-HLA mismatch between the donor and the recipient ultimately leads to the genesis of specific B cells through the B cell – T follicular helper crosstalk. Alloreactive B cells then differentiate into a diverse panel of alloreactive B cells according to their affinity for the donor molecules and to their lifespan. Once activated, these alloreactive B cells are responsible for the production of Donor Specific Antibodies (DSA) which bind the donor endothelial cells. This leads both to the activation of the complement classical pathway, and to the recruitment of innate immune cells. These two pathways are responsible for the aggression of endothelial cells, including mononuclear cell infiltration, smooth muscle cell proliferation and duplication of glomerular basement membrane, thus ultimately resulting into an allograft vasculopathy (2), the canonical lesion of chronic-active ABMR (ca-ABMR).

Another source of chronic endothelial damages in the scope of KT is the use of Calcineurin Inhibitors (CNI). Although CNIs use was a major breakthrough for KT survival and function, the acute and chronic nephrotoxicity of these drugs is now a hindrance at a time of grafts shortage and increasing number of expanded criteria donors.

Therefore, Belatacept, a co-stimulation blockade molecule, has emerged as an interesting alternative which has demonstrated its interest in situations where graft endothelium is impaired in order to improve long term eGFR, such as Extended – Criteria Donors and chronic vascular changes (3,4). Moreover, recent studies allow to broaden the indication of Belatacept to patients with a high immunological risk (5) with benefits in reducing DSA titer (6,7).

Considering these endothelial and immunological effects, this retrospective multicentric study was conducted in order to assess the beneficial effect on KT function and survival of a switch

from CNI to Belatacept in case of ca-ABMR, in which chronic production of DSA leads to chronic endothelial lesions.

Material and methods

Study population

Based on pathology databases from four different French Kidney Transplant centers (Angers, Grenoble, Paris-Creteil, Rouen), all biopsies, protocol and for cause, performed between January 2007 and January 2020 were screened and selected when they met all ca-ABMR diagnosis criteria according to Banff 2019 classification (8): (1) transplant glomerulopathy (cg>0) with no evidence of chronic thrombotic microangiopathy of glomerulonephritis or arterial intimal fibrosis of new onset, (2) linear C4d staining > 1 by immunofluorescence or > 0 by immunohistochemistry, or microvascular inflammation defined by $g + ptc \geq 2$ and (3) serologic evidence of DSA or C4d staining. All patients from with the diagnosis of ca-ABMR and switched to Belatacept were included. Control group consisted in all patients from Rouen's pathological database with histological diagnosis of ca-ABMR who remained on CNI. When several biopsies were available for one patient, only the first biopsy with the diagnosis of ca-ABMR was included. Patients whose follow-up was less than three months were excluded. Informed consent was obtained for all patients included in the study.

Belatacept administration

Before the switch to Belatacept, patients had to be seropositive for Epstein-Barr Virus. Belatacept was administered intravenously according to previously published protocol: 5 mg/kg every two weeks for five injections, then 5mg/kg every month (9). CNI were gradually reduced until discontinuation at the end of the first month.

Data collection

KT function was evaluated by eGFR according to MDRD formula (10). In the Belatacept-treated group, Day 0 (D0) was the day of first administration of Belatacept. In the control group, D0 was the day of the biopsy. Data were collected from 3 months before D0, then every 3 months for one year, then once a year until KT failure: return to dialysis, retransplantation or death. In three centers, DSA were monitored once a year with Luminex as a screening test and a single antigen beads solid phase assay (Labscreen; One Lambda) in case of positivity. The threshold for positivity was a Mean Fluorescence Intensity (MFI) above 500. In the last center, the Immucor Lifecodes test was used with a positivity threshold of Background Corrected MFI of 2000.

Statistical analysis

Quantitative data are presented with mean \pm standard deviation (SD) or median with [min - max] according to their distribution. Qualitative data are presented with number of patients and percentages. The chi-squared test was used for categorical variables, the Student's test and the Mann-Whitney U test were used for continuous variables. KT survival was assessed using Kaplan-Meier curves and log rank test. Cox proportional hazards regression was used to assess the association between KT survival and clinical, biological or pathological characteristics. A two-sided p-value < 0.05 was considered statistically significant. Due to the low number of patients monitored with Immucor (N=2), they were excluded from statistical analysis concerning DSA. Statistical analyses were conducted using GraphPad Prism version 6.04, GraphPad Software, La Jolla California USA.

Results

Patients characteristics.

Nineteen patients were switched from CNI to Belatacept post ca-ABMR and compared to 58 controls patients, with a median follow-up of 29 [4 - 125] months post conversion ([figure 1](#)).

Median age at the time of the biopsy was 49 [19 - 76] years old. Biopsy was performed 78 [4 - 140] months after KT, with mean eGFR 36.2 ± 15.6 mL/min/1.73m² and proteinuria/creatininuria ratio 1.3 ± 1.3 g/g. In the entire cohort, pathology score was cg = 1.8 ± 0.8 , g + ptc = 3.0 ± 1.1 , ci + ct = 2.6 ± 1.5 and cv + ah = 2.8 ± 1.3 . Characteristics of patients between the Belatacept-treated group and CNI-treated group are detailed in [table 1](#). Banff score was comparable between the two groups except for tubulitis: 0.4 ± 0.8 in the Belatacept-treated group versus 0.1 ± 0.2 in the control group ($p = 0.02$), and [g + ptc] score: 2.6 ± 0.8 in the Belatacept-treated group versus 3.4 ± 1.1 ($p = 0.007$). In the Belatacept-treated group, 43.1% of patients had a previous biopsy with the diagnosis of active ABMR treated by plasmapheresis, rituximab and intravenous immunoglobulins versus 25.9% in the CNI-treated group ($p = 0.2$). Despite those differences, the two groups were similar in age, eGFR and proteinuria/creatininuria ratio at baseline. In the Belatacept-treated group, there was a statistically significant decline in the MFI of immunodominant DSA from 4298 ± 3912 to 2046 ± 2701 at one year ($p = 0.03$), versus a relative stability in the CNI-treated group: 4929 ± 5265 to 4160 ± 4586 , $p = 0.2$.

Graft survival in all the cohort and risk factor for graft loss.

There was only one death in the control-group, with functioning KT. There was no acute rejection in any group. At one, two and three years, death-censored KT survival in the Belatacept-treated group was 81.3%, 71.4% and 41.6% versus 84.4%, 66.0% and 47.1% in the CNI-treated group, $p = 0.6$.

Using Cox regression, univariate analysis showed that the switch from CNI to Belatacept was not protective from graft loss, $p = 0.6$. In univariate analysis, characteristics associated with a worst KT survival were cg, [ci + ct] and cv scores with a p-value of 0.003, 0.003 and 0.0006, respectively ([table 2](#)). The eGFR at the time of the biopsy was also significantly associated with

KT survival, $p = 0.002$. The proteinuria/creatininuria ratio was almost statistically significant ($p = 0.06$). In multivariate analysis, cg and cv scores were statistically associated with graft loss Hazard Ratio (HR) = 2.21 [1.37 – 3.55], $p = 0.01$ and 1.92 [1.24 – 2.96], $p = 0.003$, respectively, while high eGFR at the time of the biopsy was protective: HR = 0.96 [0.94 – 0.99], $p = 0.004$.

Graft function at one and two years.

Eighteen patients in the Belatacept-treated group and 58 patients in the CNI-treated group were evaluated at the 12-month endpoint. Clinical and biological characteristics between groups were similar at baseline, with an eGFR = 34.1 ± 14.5 mL/min/1.73m² versus 35.7 ± 14.9 mL/min/1.73m², $p = 0.7$. There were statistically significant differences concerning Banff score: ah score = 1.7 ± 1.3 in the Belatacept-treated group versus 1.1 ± 0.9 in the CNI-treated group ($p = 0.03$), and [i + t] score = 0.7 ± 1.2 versus 1.2 ± 0.9 ($p = 0.05$). At 3 and 6 months, eGFR value in the two groups was similar: 35.9 ± 20.0 mL/min/1.73m² then 33.3 ± 19.0 mL/min/1.73m² in the Belatacept-treated group and 35.3 ± 13.0 then 33.6 ± 15.3 in the CNI-treated group. At 1 year, eGFR in the Belatacept-treated group was 30.1 ± 17.8 mL/min/1.73m² versus 29.1 ± 17.4 mL/min/1.73m², $p = 0.6$. Decline in eGFR between 1 year and Day 0 was statistically significant in the CNI-treated group ($p = 0.03$) but not in the Belatacept-treated group ($p = 0.5$), [figure 2](#).

At two years, data were available for 15 patients in the Belatacept-treated group and 53 patients in the CNI-treated group. At baseline, ah score was statistically different: 1.8 ± 1.3 and 1.1 ± 1.1 , respectively ($p = 0.03$). The [g + ptc] score was also statistically different: 2.6 ± 0.8 in the Belatacept-treated group versus 3.2 ± 1.0 in the CNI-treated group, $p = 0.03$. In the Belatacept-treated group, baseline eGFR was 34.7 ± 15.7 versus 36.0 ± 15.3 in the CNI-treated group, $p = 0.8$. In the Belatacept-treated group, eGFR at 12 and 24 months were 29.5 ± 19.3 and 27.1 ± 19.8 , respectively, compared to 28.8 ± 18.1 and 23.4 ± 17.5 in the CNI-group at the same

endpoints. These differences did not reach statistical significance. However, decline in eGFR at 1 and 2 years in the CNI-treated group was significant: $p = 0.03$ and $p = 0.0001$, respectively. Decline in eGFR in the Belatacept-treated group was not statistically significant.

Graft function in patients with a 36-month follow-up.

The 36-month data were available for 12 Belatacept-treated patients and 50 CNI-treated patients. Following switch to Belatacept, eGFR declined from 31.2 ± 14.5 mL/min/1.73m² to 26.0 ± 19.7 mL/min/1.73m² at one year, 22.4 ± 19.5 mL/min/1.73m² at two years and 22.1 ± 24.9 mL/min/1.73m² at three years. Comparatively, eGFR in the control group declined from 36.1 ± 15.7 mL/min/1.73m² at biopsy to 29.1 ± 18.6 mL/min/1.73m² at one year, 23.4 ± 18.0 mL/min/1.73m² at two years and 17.5 ± 18.0 mL/min/1.73m² at three years. There was no difference when comparing the two groups at one year ($p = 0.7$), two years ($p = 0.8$) and three years ($p = 0.9$). The delta of eGFR between 1 year and D0 was -5.1 ± 8.6 mL/min/1.73m² in the Belatacept-treated group versus -7.1 ± 13.3 mL/min/1.73m² in the CNI-treated group, $p = 0.6$. The delta of eGFR between 2 years and D0 was -8.8 ± 9.3 mL/min/1.73m² versus -12.8 ± 13.9 mL/min/1.73m², $p = 0.3$. The delta of eGFR between 3 years and D0 were -9.1 ± 14.3 mL/min/1.73m² versus -18.6 ± 15.1 mL/min/1.73m², $p = 0.05$ ([figure 3](#)).

Graft survival and function according to transplant glomerulopathy (cg).

In order to assess the impact of Belatacept in several conditions, subgroups were defined according to results from the Cox analysis. In the Belatacept-treated group, there were 5 (41.7%) patients with a transplant glomerulopathy score $cg < 2$ versus 17 (34.0%) patients in the control group. Baseline eGFR in the Belatacept-treated group and control group were 36.6 ± 15.8 mL/min/1.73m² versus 39.7 ± 18.4 mL/min/1.73m² ($p = 0.7$). Banff scores were not statistically different except for g score = 0.8 ± 0.4 in the Belatacept-treated group versus $1.6 \pm$

0.7 in the CNI-treated group, $p = 0.03$. In patients with $cg < 2$, there was no difference regarding death-censored KT survival at 1, 2 and 3 years: 85.7%, 83.3% and 60.0% in the Belatacept-treated group, respectively, versus 100.0%, 76.5% and 70.6% in the CNI-treated group, $p = 0.9$. In the Belatacept-treated group, eGFR was 30.5 ± 21.8 mL/min/1.73m² at 1 year, 27.0 ± 22.2 mL/min/1.73m² at 2 years and 28.8 ± 30.6 mL/min/1.73m² at 3 years versus 38.3 ± 21.1 mL/min/1.73m², 33.3 ± 22.5 mL/min/1.73m² and 29.9 ± 23.7 mL/min/1.73m² in the control group. These differences were not different at these three endpoints, $p = 0.5$, $p = 0.6$, $p = 0.8$, respectively.

In the subgroup with $cg \geq 2$, there was no difference at baseline with an eGFR = 28.7 ± 14.9 mL/min/1.73m² in the Belatacept-treated group versus 34.3 ± 14.1 in the CNI-treated group, $p = 0.4$. There was no statistical difference in terms of KT survival: 77.8%, 62.5% and 28.6% versus 76.3%, 61.1% and 35.3%, $p = 0.7$. eGFR at 1, 2 and 3 years within two groups were not statistically different: 22.7 ± 19.0 mL/min/1.73m², 19.2 ± 18.3 mL/min/1.73m² and 17.3 ± 21.4 mL/min/1.73m² versus 24.3 ± 15.4 mL/min/1.73m², 18.2 ± 12.7 mL/min/1.73m² and 11.2 ± 9.5 mL/min/1.73m², with $p = 0.8$, $p = 0.9$, $p = 0.9$, respectively. In the Belatacept-treated group, the delta of eGFR between year 3 and D0 was -11.6 ± 10.4 mL/min/1.73m² versus -23.1 ± 15.0 mL/min/1.73m², $p=0.06$. The other values for delta of eGFR at one, two and three years are summarized in [table 3](#).

Graft survival and function in case of CNI toxicity.

To assess the potential benefit of Belatacept in case of CNI toxicity, analyses were performed after focusing on patients with a [ci + ct] score ≥ 4 OR a [cv + ah] score ≥ 4 with 8 (66.7%) patients in the Belatacept-treated group and 24 (48.0%) patients in the control group. There was no difference at baseline, with an eGFR at 27.9 ± 13.5 mL/min/1.73m² in the Belatacept-treated group versus 29.3 ± 12.3 mL/min/1.73m² in the CNI-treated group ($p = 0.7$). Death-censored

KT survival in the Belatacept-treated group at 1, 2 and 3 years was 70.0%, 62.5% and 25% versus 70.4%, 52.0% and 37.5% in the control group, without statistically significant difference, $p = 0.8$.

In the Belatacept-treated group, eGFR at 1, 2 and 3 years was 21.9 ± 19.2 mL/min/1.73m², 21.2 ± 21.7 mL/min/1.73m², and 20.4 ± 29.1 mL/min/1.73m², respectively, versus 21.4 ± 14.0 mL/min/1.73m², 17.2 ± 13.5 mL/min/1.73m² and 13.4 ± 12.8 mL/min/1.73m² in the control group. Differences between groups were not statistically significant: $p = 0.8$, $p = 0.8$ and $p = 0.8$, respectively ([figure 4](#)). Although not statistically significant, in the Belatacept-treated group, eGFR delta between 3 years and Day 0 was -7.6 ± 17.7 mL/min/1.73m² versus -15.9 ± 10.8 mL/min/1.73m² in the CNI-treated group, $p = 0.1$.

Graft survival and function according to transplant arteriopathy (cv).

In the Belatacept-treated group, 8 (66.7%) patients had a cv score of 0 or 1 versus 28 (56.0%) patients in the CNI-treated group. Baseline eGFR was not different: 37.6 ± 13.2 mL/min/1.73m² versus 40.2 ± 16.3 mL/min/1.73m², $p = 0.8$. However, mean [ci + ct] score was 3.0 ± 1.7 in the Belatacept-treated group versus 1.8 ± 1.2 in the other group, $p = 0.02$. There was no difference of death-censored KT survival in the two groups. Mean eGFR at one year in the Belatacept-treated group was 33.2 ± 20.0 mL/min/1.73m² versus 37.1 ± 18.2 mL/min/1.73m², $p = 0.8$. At two years, eGFR = 28.7 ± 21.1 mL/min/1.73m² versus 30.1 ± 18.7 mL/min/1.73m², $p = 0.9$, and at three years: 30.6 ± 27.0 mL/min/1.73m² versus 22.5 ± 20.4 mL/min/1.73m², $p = 0.6$. The eGFR delta between 3 years and Day 0 was -7.3 ± 17.5 mL/min/1.73m² in the Belatacept-treated group versus -17.8 ± 17.5 mL/min/1.73m² in the CNI-treated group, $p = 0.1$.

In groups defined by cv score at 2 or 3, eGFR at baseline was different: 20.2 ± 1.7 mL/min/1.73m² in the Belatacept-treated group versus 30.9 ± 13.5 mL/min/1.73m² in the CNI-treated group, $p = 0.03$. This difference decreased over time: 11.5 ± 7.7 mL/min/1.73m² in the

Belatacept-treated group versus 18.9 ± 13.6 mL/min/1.73m² at one year, $p = 0.3$ and 10.0 ± 6.1 mL/min/1.73m² versus 14.8 ± 13.0 mL/min/1.73m² at two years, $p = 0.8$. At three years, all the 4 patients in the Belatacept-treated group encompassed KT loss at three years versus 72.7% in the CNI-group.

Graft survival and function according to baseline eGFR.

Median eGFR at D0 was 34.4 [12.5 – 79.7]. To determine whether the switch to Belatacept could be beneficial in early-stage of ca-ABMR, analyses were performed according to the eGFR with a cut-off of 35.0 mL/min/1.73m².

When focusing on the 4 (33.3%) patients and 24 (48.0%) controls with baseline eGFR ≥ 35.0 mL/min/1.73m², there was no difference at baseline between groups except in the cg score: 1.3 ± 1.0 in the Belatacept-treated group versus 2.3 ± 0.8 in the CNI-treated group, $p = 0.03$. Baseline eGFR were 49.3 ± 3.0 mL/min/1.73m² versus 49.4 ± 11.5 mL/min/1.73m², $p = 0.8$.

In the Belatacept-treated group, eGFR at one, two and three years was 50.6 ± 5.5 mL/min/1.73m², 47.0 ± 10.2 mL/min/1.73m², and 52.9 ± 18.4 mL/min/1.73m², respectively. In the CNI-treated group eGFR at the same endpoints was 39.5 ± 19.1 mL/min/1.73m², 33.1 ± 18.6 mL/min/1.73m² and 24.2 ± 22.0 mL/min/1.73m². These differences failed to reach statistically significance at one year ($p=0.08$) and two years ($p = 0.07$). However, at three years, p value was 0.03. More, between 1 year and Day 0, the eGFR delta was 1.3 ± 7.9 mL/min/1.73m² in the Belatacept-treated group versus -10.0 ± 16.4 mL/min/1.73m² in the other group, $p = 0.2$, Between 2 years and Day 0: -2.5 ± 12.2 mL/min/1.73m² versus -16.4 ± 16.5 mL/min/1.73m², $p = 0.1$. This difference reached statistically significance between 3 years and Day 0: 3.3 ± 19.2 mL/min/1.73m² versus -25.3 ± 17.1 mL/min/1.73m², $p = 0.005$. Death-censored KT survival was not different between groups, $p = 0.2$ ([figure 5](#)).

When considering patients with an eGFR < 35 mL/min/1.73m², there was no difference in baseline characteristics between groups. In the Belatacept-treated group, eGFR was 23.6 ± 7.6 mL/min/1.73m² at baseline, 13.7 ± 8.5 mL/min/1.73m² at one year, 10.2 ± 5.8 mL/min/1.73m² at two years and 6.7 ± 4.7 mL/min/1.73m² at three years. In the CNI-treated group, eGFR at the same time was 23.8 ± 6.0 mL/min/1.73m², 19.5 ± 12.0 mL/min/1.73m², 14.4 ± 11.9 mL/min/1.73m² and 11.4 ± 10.3 mL/min/1.73m², respectively. There was no statistically significant difference: p = 0.5, p = 0.2, p = 0.5, p = 0.2, respectively. Death-censored KT survival was also not different between the two groups, p = 0.6.

Discussion

This study aim was to assess the use of Belatacept in the setting of ca-ABMR post KT. Although mean eGFR was not statistically different between groups at 1, 2 and 3 years, switch to Belatacept resulted in a lower decline in eGFR than CNI. However, no evidence of a beneficial effect on death-censored KT survival was shown. Interestingly, DSA MFI in Belatacept-treated group decreased, versus stability in CNI-treated group. Secondary analyses were performed according to subgroups defined by identified risk factors for graft loss: cg and cv scores, baseline eGFR. Those analyses highlighted that the switch to Belatacept is of major interest when it is performed at an early stage with an eGFR ≥ 35 mL/min/1.73m², while this effect was not found on patients with transplant vasculopathy or transplant glomerulopathy.

Finally, switch to Belatacept-based regimen in case of CNI-toxicity added to ca-ABMR lesions may slow down the eGFR degradation, but to a lesser extent than in case of CNI-toxicity alone known from other studies.

To date, rejection remains the first cause of graft dysfunction, responsible for almost 50% of KT losses (1). Among types of rejection, ABMR is the major subtype leading to KT loss. The common feature of ca-ABMR is chronic vascular lesions resulting from endothelial aggression. Indeed, recognition of donor's HLA or minor histocompatibility antigens molecules expressed

on graft endothelium by the recipient's immune system induces vascular recruitment of immune effectors and complement activation (11,12). As a result endothelial cell damage occurs, with manifestations on both the micro and the macrocirculation: multilamination of the peritubular capillary, reduplication of glomerular basement membrane and fibrointimal thickening of renal arteries (13,14). Those lesions occur after a prior active ABMR (15–17), leading to irreversible transplant glomerulopathy which is associated with dismal KT prognosis (18–20). Indeed, despite reduction in DSA titer which can be reached through therapies including plasma exchange (21), Rituximab (22), or proteasome inhibitors such as Bortezomib (23), these combinations failed to demonstrate efficacy in preventing KT loss of function in the scope of ca-ABMR. Therefore, and according to latest guidelines, the aim when managing ca-ABMR is rather to stabilize KT function and limiting its degradation through usual nephroprotective therapies than to increase risks of an over-immunosuppression with therapies of unproven efficacy (24).

Belatacept is now widely used in KT, since its benefit on KT function and KT and patient survival has been proven in the BENEFIT study (25). This co-stimulation blockade molecule is known for its inhibitory activity on humoral response through the inhibition of B cell – TFh cell crosstalk (26), leading to a decreased number of activated B cell and therefore, less DSA-secreting plasma cells (27). This has been confirmed in human KT studies, and Belatacept indications have been successfully extended to immunized KT recipients (5,28), CNI-intolerant recipients from extended-criteria donors (3), and as a rescue therapy in recipients with severe vascular lesions, i.e late switch (4). Finally, it also has been shown that Belatacept-treated patients with stable function have less inflammatory and fibrogenic cells with less tubular atrophy and interstitial fibrosis as compared to CNI-treated patients (29).

Based on those studies, the hypothesis of the benefit of Belatacept on vascular and fibrotic KT secondarily to ca-ABMR was made. Although this is a retrospective study, this multicentric cohort has characteristics comparable to several studies with larger population, both in their baseline characteristics and the control group outcome (22,30,31), with a mean cg score at 1.8 ± 0.8 , $[ci + ct] = 2.6 \pm 1.5$ and $cv + ah = 2.8 \pm 1.4$, reflecting usual practices.

Recently, Kumar et al. reported their experience of Belatacept in ca-ABMR, diagnosed by standard histologic and molecular assessment (32). In this work, the switch to Belatacept improved the eGFR at 1 year compared to a propensity matched control cohort treated by CNI in which slope of decline in eGFR remained stable. Here, a such clear improvement has not been observed. This could be partially explained by a higher $[ci + ct]$ score in their control group (4.63 ± 1.99 versus 3.16 ± 0.89 , $p < 0.01$) which could worsen the eGFR evolution in this group and emphasized differences between groups. More, their much higher death-censored graft survival at 89% at 29 months versus 65% in the current study may reflect, in addition to a better evolution with Belatacept than CNI, differences in baseline characteristics of these two populations. Finally, the use of molecular assessment in the study of Kumar et al. may provide earlier diagnosis before the occurrence of irreversible histological lesions and therefore gives the opportunity of an early treatment, which is in line with the better outcomes reported when Belatacept is started when $eGFR \geq 35 \text{ mL/min/1.73m}^2$.

Despite immunological effects of Belatacept leading to a reduced DSA titer (6,7,33), which was also found in this study, there was no group of patient defined by cg score in which Belatacept could be a viable alternative to slow down KT function degradation. Indeed, and as mentioned above, this pathological pattern is irreversible and lowering DSA level does not seem to limit its aggravation, highlighting again the major interest of an early diagnosis and treatment of active ABMR, before the occurrence of transplant glomerulopathy.

The more surprising fact is the limited benefit of the switch in patients with vasculopathy or CNI toxicity associated with ca-ABMR. Indeed, in previous study (4), withdrawal of CNI in case of CNI toxicity and/or chronic vasculopathy without active or ca-ABMR was associated with an increasing eGFR around 7 mL/min/1.73m² at one year versus a loss of 3 mL/min/1.73m³ in patients who remained on CNI. More, this effect might be more significant in patients with cv score ≥ 2 as compared to patients with cv < 2 (34). Finally, there are arguments for an improvement in arterial stiffness and global cardiovascular risk factor with Belatacept as compared to other immunosuppressives regimens (35).

Here, the adjunction of an immunological factor on chronic vasculopathy erases the benefit of the nephrotoxicity relief occurring after CNI discontinuation. This highlights the two physiological processes in KT vasculopathy. On the one side, CNI-treated patients who undergo endothelial damage and vasoconstriction through endothelin production, reactive oxygen species and renin-angiotensin system activation system (36,37) may benefit from CNI discontinuation, both through the cessation of vasoconstriction of the afferent arterioles and reversal of molecular pathways alterations due to CNI. On the other side, fibroproliferative vasculopathy associated to rejection is characterized by mononuclear cell infiltrate and smooth muscle cell proliferation secondary to HLA molecule binding on endothelial cell surface (38,39) which evolves on its own, independently from CNI-associated vasculopathy. Consequently, the occurrence of chronic vascular changes secondary to ca-ABMR on previously healthy arteries free of CNI lesions may not be modified by CNI withdrawal. Beside this, in cases where ca-ABMR occurs on previously CNI-damaged vessels, the rapidity of fibroproliferative process induced by ca-ABMR associated with the dismal KT may exceed both in severity and speed the evolution of CNI-toxicity, thereby masking the known benefits

of Belatacept. In other words, the hypothesis in which the endothelium already aggressed by ca-ABMR may benefit from the switch to Belatacept in order to prevent another aggression by CNI toxicity remains to be established. Finally, the different outcomes in this cohort compared to previously published data on vascular and fibrotic KT (4,5), although immunological context differs, raises the question of the apprehension of KT vasculopathy. Considering that Banff criteria remain non-specific, it may be possible that some KT with vasculopathy do not meet ca-ABMR criteria although an immunological process is ongoing, and therefore could be put forward as candidates for a switch to Belatacept, which would not be beneficial according to this study. In the era of precision medicine, these considerations may be another argument for the need to develop everyday diagnostic and classification tools, for example molecular biology, in order to better select patients who may benefit from a switch to Belatacept (40).

This study encompasses several limitations due to its retrospective design and the number of patients included in the Belatacept-treated group. This is in line with the size of other clinical studies on Belatacept, and symptomatic of a still limited access to co-stimulation blockade agents in all KT centers, as evidenced by the multicentric inclusion performed. However, the main characteristics of the patients, both clinical and pathological, reflect usual practices faced by the clinician. Another strength of the study is the three years follow-up making possible to get closer to usual practices and therapeutic challenges of ca-ABMR: delaying KT function decline as long as possible. At last, this study points the lack of benefit when eGFR is already severely impaired, which deserves a particular attention, and may help to avoid switches to Belatacept that will not improve KT function but will expose the patient to complications, as opportunistic infections (41).

Conclusion

In the scope of ca-ABMR in KT, switch from CNI to Belatacept may be beneficial on KT function at three years by lowering its decline at 1, 2 and 3 years, especially when it is started at an early stage with an eGFR ≥ 35 mL/min/1.73m². However, it does not appear to have an effect on death-censored KT survival.

Figure legends

Figure 1: flowchart. ca-ABMR: chronic-active Antibody Mediated Rejection. CNI: Calcineurin Inhibitors.

Figure 2: Kidney Transplant (KT) function after switch from Calcineurin Inhibitors (CNI) to Belatacept. In the Belatacept-treated group, Day 0 (D0) is the day of the switch. In the CNI-treated group, D0 is the day of the biopsy. Up: KT function at one year. In the Belatacept-treated group, there was no statistically significant difference between D0 and 1 year while this difference was significant in the CNI-treated group: alteration of eGFR from 35.7 ± 14.9 mL/min/1.73m² to 29.1 ± 17.4 mL/min/1.73m², $p = 0.03$. ca-ABMR: chronic-active Antibody Mediated Rejection, eGFR: estimated Glomerular Filtration Rate, CNI: Calcineurin Inhibitors.

Figure 3: Death-censored Kidney Transplant (KT) survival and evolution of eGFR at 3 years after switch from Calcineurin Inhibitors (CNI) to Belatacept. KT survival was not statistically different between groups. eGFR between groups were not statistically different at these endpoints. Decline in KT function, represented by the delta of eGFR between 3 years and Day 0, was higher in the CNI-treated group: -18.6 ± 15.1 mL/min/1.73m² versus -9.1 ± 14.3 mL/min/1.73m², $p = 0.05$. ca-ABMR: chronic-active Antibody Mediated Rejection, eGFR: estimated Glomerular Filtration Rate, CNI: Calcineurin Inhibitors.

Figure 4: Death-censored Kidney Transplant (KT) survival and evolution of eGFR at 3 years after switch from Calcineurin Inhibitors (CNI) to Belatacept in patients with pathological signs of CNI-toxicity, defined by a [ci + ct] score ≥ 4 OR [cv + ah] score ≥ 4 . Death-censored KT survival was not different between groups ($p = 0.08$). Although not statistically significant, decline in eGFR in the CNI-treated group was higher than decline in the Belatacept-treated

group. ca-ABMR: chronic-active Antibody Mediated Rejection, eGFR: estimated Glomerular Filtration Rate, CNI: Calcineurin Inhibitors.

Figure 5: Death-censored Kidney Transplant (KT) survival and evolution of eGFR at 3 years after switch from Calcineurin Inhibitors (CNI) to Belatacept according to baseline.

In the analyses with a baseline eGFR < 35 mL/min/1.73m², Death-censored KT survival was not different between groups. The two groups encompassed severe decline in eGFR across years.

In the analyses with a baseline eGFR ≥ 35 mL/min/1.73m², Death-censored KT survival was not statistically different between groups (p = 0.2). In the Belatacept-treated group, eGFR was stable during the follow-up: Delta 3 years – Day 0 = 3.3 ± 19.2 mL/min/1.73m², while patients in the CNI-treated group encompassed severe decline in eGFR: delta 3 years – Day 0 = -25.3 ± 17.1 mL/min/1.73m², p = 0.005. ca-ABMR: chronic-active Antibody Mediated Rejection, eGFR: estimated Glomerular Filtration Rate, CNI: Calcineurin Inhibitors.

References

1. Sellarés J, Freitas DG de, Mengel M, Reeve J, Einecke G, Sis B, et al. Understanding the Causes of Kidney Transplant Failure: The Dominant Role of Antibody-Mediated Rejection and Nonadherence. *Am J Transplant*. 2012;12(2):388–99.
2. Pouliquen E, Koenig A, Chen CC, Sicard A, Rabeyrin M, Morelon E, et al. Recent advances in renal transplantation: antibody-mediated rejection takes center stage. *F1000prime Rep*. 2015;7:51.
3. Le Meur Y, Aulagnon F, Bertrand D, Heng AE, Lavaud S, Caillard S, et al. Effect of an Early Switch to Belatacept Among Calcineurin Inhibitor-Intolerant Graft Recipients of Kidneys From Extended-Criteria Donors. *Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg*. 2016;16(7):2181–6.
4. Bertrand D, Cheddani L, Etienne I, François A, Hanoy M, Laurent C, et al. Belatacept Rescue Therapy in Kidney Transplant Recipients With Vascular Lesions: A Case Control Study. *Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg*. 2017 Nov;17(11):2937–44.
5. Leibler C, Matignon M, Moktefi A, Samson C, Zarour A, Malard S, et al. Belatacept in renal transplant recipient with mild immunologic risk factor: A pilot prospective study (BELACOR). *Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg*. 2019;19(3):894–906.
6. Kim EJ, Kwun J, Gibby AC, Hong JJ, Farris AB, Iwakoshi NN, et al. Costimulation blockade alters germinal center responses and prevents antibody-mediated rejection. *Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg*. 2014 Jan;14(1):59–69.
7. Bray RA, Gebel HM, Townsend R, Roberts ME, Polinsky M, Yang L, et al. Posttransplant reduction in preexisting donor-specific antibody levels after belatacept- versus cyclosporine-based immunosuppression: Post hoc analyses of BENEFIT and BENEFIT-EXT. *Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg*. 2018;18(7):1774–82.
8. Loupy A, Haas M, Roufosse C, Naesens M, Adam B, Afrouzian M, et al. The Banff 2019 Kidney Meeting Report (I): Updates on and clarification of criteria for T cell- and antibody-mediated rejection. *Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg*. 2020 May 28;
9. Rostaing L, Massari P, Garcia VD, Mancilla-Urrea E, Nainan G, del Carmen Rial M, et al. Switching from calcineurin inhibitor-based regimens to a belatacept-based regimen in renal transplant recipients: a randomized phase II study. *Clin J Am Soc Nephrol CJASN*. 2011 Feb;6(2):430–9.
10. Froissart M, Rossert J, Jacquot C, Paillard M, Houillier P. Predictive performance of the modification of diet in renal disease and Cockcroft-Gault equations for estimating renal function. *J Am Soc Nephrol JASN*. 2005 Mar;16(3):763–73.
11. Mauiyyedi S, Pelle PD, Saidman S, Collins AB, Pascual M, Tolckoff-Rubin NE, et al. Chronic humoral rejection: identification of antibody-mediated chronic renal allograft rejection by C4d deposits in peritubular capillaries. *J Am Soc Nephrol JASN*. 2001 Mar;12(3):574–82.
12. Willicombe M, Brookes P, Sergeant R, Santos-Nunez E, Steggar C, Galliford J, et al. De Novo DQ Donor-Specific Antibodies Are Associated With a Significant Risk of Antibody-Mediated Rejection and Transplant Glomerulopathy. *Transplant J*. 2012 Jul 27;94(2):172–7.
13. Loupy A, Lefaucheur C. Antibody-Mediated Rejection of Solid-Organ Allografts. *N Engl J Med*. 2018 20;379(12):1150–60.
14. Hill GS, Nochy D, Bruneval P, Duong van Huyen JP, Glotz D, Suberbielle C, et al. Donor-specific antibodies accelerate arteriosclerosis after kidney transplantation. *J Am Soc Nephrol JASN*. 2011 May;22(5):975–83.
15. Gloor JM, Cosio FG, Rea DJ, Wadei HM, Winters JL, Moore SB, et al. Histologic findings one year after positive crossmatch or ABO blood group incompatible living donor

- kidney transplantation. *Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg.* 2006 Aug;6(8):1841–7.
16. Filippone EJ, McCue PA, Farber JL. Transplant glomerulopathy. *Mod Pathol Off J U S Can Acad Pathol Inc.* 2018;31(2):235–52.
 17. Haas M. The relationship between pathologic lesions of active and chronic antibody-mediated rejection in renal allografts. *Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg.* 2018;18(12):2849–56.
 18. Viglietti D, Loupy A, Aubert O, Bestard O, Duong Van Huyen J-P, Taupin J-L, et al. Dynamic Prognostic Score to Predict Kidney Allograft Survival in Patients with Antibody-Mediated Rejection. *J Am Soc Nephrol JASN.* 2018;29(2):606–19.
 19. Lesage J, Noël R, Lapointe I, Côté I, Wagner E, Déry O, et al. Donor-specific antibodies, C4d and their relationship with the prognosis of transplant glomerulopathy. *Transplantation.* 2015 Jan;99(1):69–76.
 20. Patri P, Seshan SV, Matignon M, Desvaux D, Lee JR, Lee J, et al. Development and validation of a prognostic index for allograft outcome in kidney recipients with transplant glomerulopathy. *Kidney Int.* 2016 Feb;89(2):450–8.
 21. Wan SS, Ying TD, Wyburn K, Roberts DM, Wyld M, Chadban SJ. The Treatment of Antibody-Mediated Rejection in Kidney Transplantation: An Updated Systematic Review and Meta-Analysis. *Transplantation.* 2018;102(4):557–68.
 22. Moreso F, Crespo M, Ruiz JC, Torres A, Gutierrez-Dalmau A, Osuna A, et al. Treatment of chronic antibody mediated rejection with intravenous immunoglobulins and rituximab: A multicenter, prospective, randomized, double-blind clinical trial. *Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg.* 2018;18(4):927–35.
 23. Eskandary F, Regele H, Baumann L, Bond G, Kozakowski N, Wahrmann M, et al. A Randomized Trial of Bortezomib in Late Antibody-Mediated Kidney Transplant Rejection. *J Am Soc Nephrol JASN.* 2018;29(2):591–605.
 24. Schinstock CA, Mannon RB, Budde K, Chong AS, Haas M, Knechtle S, et al. Recommended Treatment for Antibody-mediated Rejection After Kidney Transplantation: The 2019 Expert Consensus From the Transplantation Society Working Group. *Transplantation.* 2020 May;104(5):911–22.
 25. Vincenti F, Rostaing L, Grinyo J, Rice K, Steinberg S, Gaité L, et al. Belatacept and Long-Term Outcomes in Kidney Transplantation. *N Engl J Med.* 2016 Jan 28;374(4):333–43.
 26. Leibler C, Thiolat A, Hénique C, Samson C, Pilon C, Tamagne M, et al. Control of Humoral Response in Renal Transplantation by Belatacept Depends on a Direct Effect on B Cells and Impaired T Follicular Helper-B Cell Crosstalk. *J Am Soc Nephrol JASN.* 2018 Mar;29(3):1049–62.
 27. Leibler C, Thiolat A, Elsner RA, Karoui KE, Samson C, Grimbert P. Costimulatory blockade molecules and B-cell-mediated immune response: current knowledge and perspectives. *Kidney Int.* 2019 Apr 1;95(4):774–86.
 28. Sethi S, Najjar R, Peng A, Choi J, Lim K, Vo A, et al. Outcomes of Conversion From Calcineurin Inhibitor to Belatacept-based Immunosuppression in HLA-sensitized Kidney Transplant Recipients. *Transplantation.* 2020 Jul;104(7):1500–7.
 29. Furuzawa-Carballeda J, Uribe-Urbe NO, Arreola-Guerra JM, Reyes-Acevedo R, Vilatobá M, López-Toledo A, et al. Tissue talks: immunophenotype of cells infiltrating the graft explains histological findings and the benefits of belatacept at 10 years. *Clin Exp Immunol.* 2019;197(2):250–61.
 30. Aubert O, Loupy A, Hidalgo L, Duong van Huyen J-P, Higgins S, Viglietti D, et al. Antibody-Mediated Rejection Due to Preexisting versus De Novo Donor-Specific Antibodies in Kidney Allograft Recipients. *J Am Soc Nephrol JASN.* 2017 Jun;28(6):1912–23.
 31. Haas M, Mirocha J, Reinsmoen NL, Vo AA, Choi J, Kahwaji JM, et al. Differences in

- pathologic features and graft outcomes in antibody-mediated rejection of renal allografts due to persistent/recurrent versus de novo donor-specific antibodies. *Kidney Int.* 2017;91(3):729–37.
32. Kumar D, Raynaud M, Chang J, Reeve J, Yakubu I, Kamal L, et al. Impact of Belatacept Conversion on Renal Function, Histology and Gene Expression in Kidney Transplant Patients With Chronic Active Antibody-mediated Rejection. *Transplantation.* 2020 Apr 17;
 33. Parsons RF, Zahid A, Bumb S, Decker H, Sullivan HC, Eun-Hyung Lee F, et al. The impact of belatacept on third-party HLA alloantibodies in highly sensitized kidney transplant recipients. *Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg.* 2020;20(2):573–81.
 34. Pérez-Sáez MJ, Yu B, Uffing A, Murakami N, Borges TJ, Azzi J, et al. Conversion from tacrolimus to belatacept improves renal function in kidney transplant patients with chronic vascular lesions in allograft biopsy. *Clin Kidney J.* 2019 Aug;12(4):586–91.
 35. Melilli E, Manonelles A, Montero N, Grinyo J, Martinez-Castelao A, Bestard O, et al. Impact of immunosuppressive therapy on arterial stiffness in kidney transplantation: are all treatments the same? *Clin Kidney J.* 2018 Jun;11(3):413–21.
 36. Leal R, Tsapepas D, Crew RJ, Dube GK, Ratner L, Batal I. Pathology of Calcineurin and Mammalian Target of Rapamycin Inhibitors in Kidney Transplantation. *Kidney Int Rep.* 2018 Mar;3(2):281–90.
 37. Vanhove T, Goldschmeding R, Kuypers D. Kidney Fibrosis: Origins and Interventions. *Transplantation.* 2017 Apr;101(4):713–26.
 38. Jindra PT, Jin Y-P, Rozengurt E, Reed EF. HLA class I antibody-mediated endothelial cell proliferation via the mTOR pathway. *J Immunol Baltim Md 1950.* 2008 Feb 15;180(4):2357–66.
 39. Zhang X, Valenzuela NM, Reed EF. HLA class I antibody-mediated endothelial and smooth muscle cell activation. *Curr Opin Organ Transplant.* 2012 Aug;17(4):446–51.
 40. Halloran PF, Famulski KS, Reeve J. Molecular assessment of disease states in kidney transplant biopsy samples. *Nat Rev Nephrol.* 2016;12(9):534–48.
 41. Bertrand D, Chavarot N, Gatault P, Garrouste C, Bouvier N, Grall-Jezequel A, et al. Opportunistic infections after conversion to belatacept in kidney transplantation. *Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc.* 2020 01;35(2):336–45.

Tables

Table 1

Characteristics	Belatacept-treated N=19	CNI-treated N=58	p-value
Age at transplantation, years	36 [9 - 71]	43 [15 - 74]	0.5
Female, n (%)	8 (42.1)	18 (31.0)	0.9
Cause of ESRD, n (%)			0.3
IgA nephropathy	2 (10.5)	17 (29.3)	
Diabetes	0	2 (34.5)	
Nephrosclerosis	2 (10.5)	4 (6.9)	
Other glomerulonephritis	3 (15.8)	4 (6.9)	
Cystic renal disease	2 (10.5)	7 (12.1)	
Tubulointerstitial or uropathy	7 (36.8)	12 (20.7)	
Other	2 (10.5)	2 (34.5)	
Unknown	1 (5.3)	10 (17.2)	
Prior solid organ transplantation, n (%)	3 (15.8)	7 (12.1)	0.7
Donor type, n (%)			0.8
Deceased	17 (89.5)	53 (91.4)	
Induction therapy, n (%)			0.7
Basiliximab	10 (52.6)	26 (44.8)	
Antithymoglobulin	9 (47.4)	32 (55.2)	
CNI type at biopsy, n (%)			0.08
Tacrolimus	13 (68.4)	24 (41.4)	
Ciclosporin	6 (10.3)	29 (50.0)	
mTOR inhibitor, n (%)	0	5 (8.6)	
MFI of immunodominant DSA	4298 ± 3912	4929 ± 5265	0.9
Corticosteroids at biopsy, n (%)	13 (68.4)	27 (46.6)	0.1
Corticosteroids after biopsy, n (%)	12 (63.2)	44 (75.9)	0.3
Anterior cellular rejection, n (%)	6 (31.6)	13 (22.4)	0.4
Previous treatment of active ABMR, n (%)	8 (42.1)	15 (25.9)	0.2
Year of biopsy, n (%)			0.05
Before 2014	10 (52.6)	44 (75.9)	
After 2015	9 (47.4)	14 (24.1)	
Time between KT and biopsy, months	80 [12 - 435]	75 [4 - 376]	0.9
eGFR 3 months before biopsy, mL/min/1.73m ²	38.3 ± 19.0	35.7 ± 13.0	0.5
eGFR at biopsy, mL/min/1.73m ²	37.9 ± 17.9	35.7 ± 14.9	0.6
Proteinuria/creatininuria ratio at biopsy, g/g	0.8 ± 1.1	1.3 ± 1.2	0.2
Banff score			
cg	1.6 ± 1.0	1.8 ± 0.8	0.4
ci	1.8 ± 1.0	1.5 ± 0.8	0.2
ct	1.4 ± 0.9	1.0 ± 0.8	0.1
cv	1.1 ± 1.0	1.3 ± 0.9	0.3
mm	0.8 ± 0.8	1.2 ± 0.8	0.8
ptc	1.1 ± 0.8	1.6 ± 0.9	0.05
t	0.3 ± 0.7	0.1 ± 0.2	0.02
i	0.5 ± 0.6	0.6 ± 0.6	0.5
g	1.5 ± 0.6	1.8 ± 0.6	0.06
ah	1.7 ± 1.3	1.6 ± 1.1	0.6
v	0.1 ± 0.5	0 ± 0	0.08
g + ptc	2.6 ± 0.8	3.4 ± 1.1	0.007
i + t	0.7 ± 1.2	0.6 ± 0.7	0.6
ci + ct	3.2 ± 1.8	2.5 ± 1.5	0.1
cv + ah	2.8 ± 1.2	2.9 ± 1.4	0.8
ti	1.4 ± 0.9	1.0 ± 0.9	0.1
i-IFTA	1.8 ± 0.9	1.5 ± 0.8	0.1
Time between biopsy and switch to Belatacept, days	44 [28 - 175]	NA	
Time of follow-up, months	23 [4 - 87]	80 [11 - 125]	0.1

Table 1: characteristics at baseline. Results for quantitative data are median [min – max] and mean \pm standard deviation. CNI: Calcineurin Inhibitors, ESRD: End-Stage Renal Disease, MFI: Mean Fluorescence Intensity, DSA: Donor-Specific-Antibody, eGFR: estimated Glomerular Filtration Rate (MDRD), ABMR: Antibody Mediated Rejection, KT: Kidney Transplant, NA: not applicable, IFTA: Interstitial Fibrosis and Tubular Atrophy.

Table 2

Characteristic	Univariate analysis	Multivariate analysis		
	p	HR	95% CI	p
Donor type	0.8	/		
Sex	0.2	/		
Age at the biopsy	0.9	/		
Delay between KT and biopsy	0.8	/		
eGFR at the biopsy	0.0002	0.96	[0.94 – 0.99]	0.04
Proteinuria/creatininuria ratio at the biopsy	0.06	0.87	[0.68 – 1.13]	0.3
cg score	0.003	2.21	[1.37 – 3.55]	0.01
cv score	0.0006	1.92	[1.24 – 2.96]	0.03
ah score	0.4	/		
g + ptc score	0.8	/		
i + t score	0.2	/		
ci + ct score	0.003	1.16	[0.90 – 1.50]	0.2
Switch to Belatacept	0.6	/		

Table 2: risk factors for graft loss according to baseline characteristics. HR: Hazard Ratio, CI: confidence interval, KT: Kidney Transplant. eGFR: estimated Glomerular Filtration Rate, cg: transplant glomerulopathy, cv: transplant arteriopathy, ah: arteriolar hyalinosis, g: glomerulitis, ptc: peritubular capillaritis, i: interstitial inflammation, t: tubulitis, ci: interstitial fibrosis, ct: tubular atrophy

Table 3

All cohort	Delta 1 year – Day 0	Delta 2 years – Day 0	Delta 3 years – Day 0
Belatacept-treated	- 5.2 ± 8.6	- 8.8 ± 9.3	- 9.1 ± 14.3
CNI-treated	- 7.1 ± 13.3	- 12.8 ± 13.9	- 18.6 ± 15.1
p value	0.6	0.3	0.05
cg score < 2	Delta 1 year – Day 0	Delta 2 years – Day 0	Delta 3 years – Day 0
Belatacept-treated	- 3.8 ± 11.1	- 7.4 ± 11.5	- 5.6 ± 19.3
CNI-treated	- 1.4 ± 9.9	- 6.4 ± 11.0	-9.9 ± 11.1
p value	0.7	0.9	0.5
cg score ≥ 2	Delta 1 year – Day 0	Delta 2 years – Day 0	Delta 3 years – Day 0
Belatacept-treated	- 6.1 ± 7.1	- 9.7 ± 8.3	- 11.6 ± 10.4
CNI-treated	- 9.9 ± 14.1	- 16.0 ± 14.2	- 23.1 ± 15.0
p value	0.5	0.3	0.06
CNI toxicity : no	Delta 1 year – Day 0	Delta 2 years – Day 0	Delta 3 years – Day 0
Belatacept-treated	- 3.3 ± 7.8	- 12.8 ± 3.7	- 12.0 ± 0.8
CNI-treated	- 6.3 ± 15.4	- 13.4 ± 17.2	- 21.1 ± 18.0
p value	0.7	0.9	0.3
CNI toxicity : yes	Delta 1 year – Day 0	Delta 2 years – Day 0	Delta 3 years – Day 0
Belatacept-treated	- 6.1 ± 9.2	- 6.8 ± 10.8	- 7.6 ± 17.7
CNI-treated	- 7.9 ± 10.9	- 12.1 ± 9.3	- 15.9 ± 10.8
p value	0.7	0.2	0.1
cv score < 2	Delta 1 year – Day 0	Delta 2 years – Day 0	Delta 3 years – Day 0
Belatacept-treated	- 4.6 ± 9.7	- 9.3 ± 11.1	- 7.3 ± 17.5
CNI-treated	- 3.2 ± 13.3	- 10.2 ± 15.6	- 17.8 ± 17.5
p value	0.8	0.9	0.1
cv score ≥ 2	Delta 1 year – Day 0	Delta 2 years – Day 0	Delta 3 years – Day 0
Belatacept-treated	- 6.3 ± 7.1	- 7.8 ± 5.5	- 12.8 ± 3.3
CNI-treated	-12.0 ± 12.0	- 16.1 ± 10.7	- 19.6 ± 11.6
p value	0.4	0.1	0.3
Baseline eGFR ≥ 35	Delta 1 year – Day 0	Delta 2 years – Day 0	Delta 3 years – Day 0
Belatacept-treated	1.3 ± 7.9	- 2.5 ± 12.2	3.3 ± 19.2
CNI-treated	- 10.0 ± 16.4	- 16.4 ± 16.5	- 25.3 ± 17.1
p value	0.2	0.1	0.005
Baseline eGFR < 35	Delta 1 year – Day 0	Delta 2 years – Day 0	Delta 3 years – Day 0
Belatacept-treated	- 8.4 ± 7.3	- 11.9 ± 6.3	- 15.3 ± 5.6
CNI-treated	- 4.3 ± 9.2	- 9.4 ± 10.2	- 12.4 ± 9.7
p value	0.3	0.5	0.4

Table 3: delta of eGFR (mL/min/1.73m²) between 1 year and Day 0, 2 years and Day 0 and 3 years and Day 0, between Belatacept-treated group and CNI-treated group, according to Banff score and baseline eGFR. Differences which reached or trended to statistical significance are highlighted. CNI: Calcineurin Inhibitors, cg: transplant glomerulopathy, cv: transplant vasculopathy, eGFR: estimated Glomerular Filtration Rate.

Figures
Figure 1




Figure 2







Figure 3




No. of events/No. at risk	Baseline	1 year	2 years	3 years
Belatacept-treated	0/19	3/13	4/10	7/5
CNI-treated	0/58	9/49	18/35	17/24




	Delta 1 year – Day 0	Delta 2 years – Day 0	Delta 3 years – Day 0
Belatacept-treated	- 5.1 ± 8.6	- 8.8 ± 9.3	- 9.1 ± 14.3
CNI-treated	- 7.1 ± 13.3	- 12.8 ± 13.9	- 18.6 ± 15.1
p value	0.6	0.3	0.05

Figure 4




No. of events/No. at risk	Baseline	1 year	2 years	3 years
Belatacept	0/11	3/7	3/5	6/2
CNI	0/27	8/19	12/13	15/9



	Delta 1 year – Day 0	Delta 2 years – Day 0	Delta 3 years – Day 0
Belatacept-treated	- 6.1 ± 9.2	- 6.8 ± 10.8	- 7.6 ± 17.7
CNI-treated	- 7.9 ± 10.9	- 12.1 ± 9.3	- 15.9 ± 10.8
p value	0.7	0.2	0.1

Figure 5



Switch from Calcineurin Inhibitors to Belatacept in Kidney Transplant patients with chronic-active Antibody Mediated Rejection results in a lower decline in Kidney Transplant function at three years.

Introduction:

Chronic-active Antibody Mediated Rejection (ca-ABMR) in Kidney Transplant (KT) lacks effective treatment. Hence, latest guidelines recommend usual nephroprotective therapies in which limiting nephrotoxicity is paramount. Belatacept which usefulness in Extended Criteria Donors and chronic vascular changes has been shown could be an interesting alternative to Calcineurin Inhibitors (CNI). This study aims to evaluate if switch from CNI to Belatacept is beneficial on KT survival and function in ca-ABMR.

Methods:

Patients with the diagnosis of ca-ABMR and switched to Belatacept between 2012 and 2020 in four French KT centers were retrospectively included.

Results:

Nineteen patients were switched from CNI to Belatacept and compared to 58 controls with a median follow-up of 29 [4 - 125] months. Biopsy was performed 78 [4 - 140] months after KT, with a mean estimated Glomerular Filtration Rate (eGFR) of 36.2 ± 15.6 mL/min/1.73m².

There was no difference of eGFR at baseline, one, two and three years: 31.2 ± 14.5 , 26.0 ± 19.7 , 22.4 ± 19.5 and 22.1 ± 24.9 mL/min/1.73m², respectively, in the Belatacept-treated group, versus 36.1 ± 15.7 , 29.1 ± 18.6 , 23.4 ± 18.0 and 17.5 ± 18.0 mL/min/1.73m² in the CNI-treated group. The delta of eGFR between 3 years and Day 0 was -9.1 ± 14.3 mL/min/1.73m² in the Belatacept-treated group versus -18.6 ± 15.1 mL/min/1.73m², $p = 0.05$. This difference was increased when focusing on the subgroup with a baseline eGFR ≥ 35 mL/min/1.73m²: 3.3 ± 19.2 versus -25.3 ± 17.1 mL/min/1.73m², $p = 0.005$. However, death-censored survival was similar in the two groups at one, two and three years: 81.3%, 71.4% and 41.6%, respectively, in the Belatacept-treated group, versus 84.4%, 66.0% and 47.1%, $p = 0.6$.

Conclusion:

Switch from CNI to Belatacept may lower decline of eGFR at three years, especially when it is started at an early stage. However, it does not appear to have an effect on death-censored KT survival.

Keywords:

Chronic-active Antibody Mediated Rejection; Belatacept; Kidney Transplant; Chronic Allograft Nephropathy; Immunosuppressive agent;